Sunitinib

Commodity a leaf — nothing below it, 8 links to KBLI

Level: Commodity
Parent: 51112000
Below: 0
Links · KBLI: 8

Definition

UNSPSC 51112009

This classification denotes a tyrosine kinase inhibitor and angiogenesis activator inhibitor with the molecular formula C22H27FN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V99T50803M, chemically known as 1h-pyrrole-3-carboxamide, n-(2-(diethylamino)ethyl)-5-((z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-2,4-dimethyl- but generally known as sunitinib, which bears US NIH Compound Identifier 5329102. European Medicines Agency schedules Sunitinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22321. The term SUNITINIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, No. 1, 2006, List 55). World Health Organization schedules sunitinib in its Anatomical Therapeutic Chemical (ATC) Classification. SUNITINIB is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sunitinib under HS 29337900 and SITC 51561. As of Q4 2014, SUNITINIB remains the US FDA Preferred Term for this commodity. Sunitinib bears US NLM identifiers UMLS ID C1176020 and NCI Concept Code C71622. SMILES: FC1CC2/C(=C/C3[NH]C(C(C3C)C(=O)NCCN(CC)CC)C)C(=O)NC2CC1.

Same parent

Under 51112000 · 37

51112001 Capecitabine Commodity 51112002 Dasatinib Commodity 51112003 Erlotinib Commodity 51112004 Gefitinib Commodity 51112005 Imatinib Commodity 51112006 Pazopanib Commodity 51112007 Semaxanib Commodity 51112008 Sorafenib Commodity 51112009 Sunitinib You are here 51112010 Vandetanib Commodity 51112011 Vatalanib Commodity 51112012 Afatinib Commodity 51112013 Dasatinib hydrate Commodity 51112014 Erlotinib hydrochloride Commodity 51112015 Imatinib mesiate or mesylate Commodity 51112016 Sorafenib tosylate Commodity 51112017 Sunitinib malate Commodity 51112018 Vatalanib succinate Commodity 51112019 Bosutinib Commodity 51112020 Ceritinib Commodity 51112021 Palbociclib Commodity 51112022 Ibrutinib Commodity 51112023 Ruxolitinib Commodity 51112024 Idelalisib Commodity 51112025 Trametinib Commodity 51112026 Acalabrutinib Commodity 51112027 Cabozantinib Commodity 51112028 Regorafenib Commodity 51112029 Nintedanib Commodity 51112030 Abemaciclib Commodity 51112031 Ribociclib Commodity 51112032 Lenvatinib Commodity 51112033 Crizotinib Commodity 51112034 Baricitinib Commodity 51112035 Osimertinib Commodity 51112036 Alectinib Commodity 51112037 Midostaurin Commodity

Activities that produce or sell this

KBLI · 8

Inherited from family 51110000.

21012 Industri Produk Farmasi untuk Manusia Sub-class 21013 Industri Produk Farmasi untuk Hewan Sub-class 46441 Perdagangan Besar Sediaan Farmasi untuk Manusia Sub-class 46442 Perdagangan Besar Sediaan Farmasi untuk Hewan Sub-class 46902 Perdagangan Besar Berbagai Macam Barang Selain di Grosir/Perkulakan Swalayan Sub-class 47721 Perdagangan Eceran Sediaan Farmasi untuk Manusia di Apotek Sub-class 47722 Perdagangan Eceran Sediaan Farmasi untuk Manusia Selain di Apotek Sub-class 47726 Perdagangan Eceran Obat Farmasi untuk Hewan Sub-class

Warning
The links were generated with a large language model (Gemini 3.5 Flash), matching UNSPSC at the family level to KBLI at the kelompok level. Some of them maybe are wrong, so check any link you intend to rely on.